Strategies, Techniques, Applications and Resources 149
ISBN: 978-93-91303-83-9 DOI: https://www.doi.org/10.47715/JPC.B.978-93-91303-83-9
25. Peng, J., Sengupta, S., & Jordan, V. C. (2009). Potential of selective estrogen receptor modulators as
treatments and preventives of breast cancer. Anti-Cancer Agents in Medicinal Chemistry, 9(5), 481–499.
https://doi.org/10.2174/187152009788451833
26. Sang, Y., Chen, B., Song, X., Li, Y., Liang, Y., Han, D., Zhang, N., Zhang, H., Liu, Y., Chen, T., Li, C.,
Wang, L., Zhao, W., & Yang, Q. (2019). circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor
Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer. Molecular Therapy: The
Journal of the American Society of Gene Therapy, 27(9), 1638–1652.
https://doi.org/10.1016/j.ymthe.2019.05.011
27. Dhiman, A., Sharma, R., & Singh, R. K. (2022). Target-based anticancer indole derivatives and insight into
structure‒activity relationship: A mechanistic review update (2018-2021). Acta Pharmaceutica Sinica. B,
12(7), 3006–3027. https://doi.org/10.1016/j.apsb.2022.03.021
28. Kumari, A., & Singh, R. K. (2019). Medicinal chemistry of indole derivatives: Current to future therapeutic
prospectives. Bioorganic Chemistry, 89, 103021. https://doi.org/10.1016/j.bioorg.2019.103021
29. Akash, M. S. H., Fatima, M., Rehman, K., Rehman, Q., Chauhdary, Z., Nadeem, A., & Mir, T. M. (2023).
Resveratrol Mitigates Bisphenol A-Induced Metabolic Disruptions: Insights from Experimental Studies.
Molecules (Basel, Switzerland), 28(15), 5865. https://doi.org/10.3390/molecules28155865
30. Perrot-Applanat, M., Kolf-Clauw, M., Michel, C., & Beausoleil, C. (2018). Alteration of mammary gland
development by bisphenol a and evidence of a mode of action mediated through endocrine disruption.
Molecular and Cellular Endocrinology, 475, 29–53. https://doi.org/10.1016/j.mce.2018.06.015
31. Oeser, P., Koudelka, J., Petrenko, A., & Tobrman, T. (2021). Recent Progress Concerning the N-Arylation
of Indoles. Molecules, 26(16), 5079. https://doi.org/10.3390/molecules26165079
32. Macdonough, M. T., Strecker, T. E., Hamel, E., Hall, J. J., Chaplin, D. J., Trawick, M. L., & Pinney, K. G.
(2013). Synthesis and biological evaluation of indole-based, anti-cancer agents inspired by the vascular
disrupting agent 2-(3’-hydroxy-4’-methoxyphenyl)-3- (3″,4″,5″-trimethoxybenzoyl)-6-methoxyindole
(OXi8006). Bioorganic & Medicinal Chemistry, 21(21), 6831–6843.
https://doi.org/10.1016/j.bmc.2013.07.028
33. Nishino, Y., Schneider, M. R., Michna, H., & von Angerer, E. (1991). Pharmacological characterization
of a novel oestrogen antagonist, ZK 119010, in rats and mice. The Journal of Endocrinology, 130(3), 409–
414. https://doi.org/10.1677/joe.0.1300409
34. Kung, A. (2012). Bazedoxifene: A new selective estrogen-receptor modulator for postmenopausal
osteoporosis. International Journal of Clinical Rheumatology, 7(6), 583–590.
https://doi.org/10.2217/ijr.12.47Wardell, S. E., Ellis, M. J., Alley, H. M., Eisele, K., VanArsdale, T., Dann,
S. G., Arndt, K. T., Primeau, T., Griffin, E., Shao, J., Crowder, R., Lai, J.-P., Norris, J. D., McDonnell,
35. D. P., & Li, S. (2015). Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of
Endocrine Therapy-Resistant Breast Cancer. Clinical Cancer Research: An Official Journal of the American
Association for Cancer Research, 21(22), 5121–5130. https://doi.org/10.1158/1078-0432.CCR-15-0360
36. Stump, A. L., Kelley, K. W., & Wensel, T. M. (2007). Bazedoxifene: A Third-Generation Selective Estrogen
Receptor Modulator for Treatment of Postmenopausal Osteoporosis. Annals of Pharmacotherapy, 41(5),
833–839. https://doi.org/10.1345/aph.1H428
37. de Villiers, T. J., Chines, A. A., Palacios, S., Lips, P., Sawicki, A. Z., Levine, A. B., Codreanu, C., Kelepouris,
N., & Brown, J. P. (2011). Safety and tolerability of bazedoxifene in postmenopausal women with
osteoporosis: Results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporosis International:
A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the
National Osteoporosis Foundation of the USA, 22(2), 567–576. https://doi.org/10.1007/s00198-010-1302-6
38. Long, X., & Nephew, K. P. (2006). Fulvestrant (ICI 182,780)-dependent Interacting Proteins Mediate
Immobilization and Degradation of Estrogen Receptor-α. Journal of Biological Chemistry, 281(14), 9607–
9615. https://doi.org/10.1074/jbc.M510809200
39. Movérare-Skrtic, S., Börjesson, A. E., Farman, H. H., Sjögren, K., Windahl, S. H., Lagerquist, M. K.,
Andersson, A., Stubelius, A., Carlsten, H., Gustafsson, J.-Å., & Ohlsson, C. (2014). The estrogen receptor
antagonist ICI 182,780 can act both as an agonist and an inverse agonist when estrogen receptor α AF-2 is
modified. Proceedings of the National Academy of Sciences of the United States of America, 111(3), 1180–
1185. https://doi.org/10.1073/pnas.1322910111
40. Li, Y., Orahoske, C. M., Urmetz, S. M., Zhang, W., Huang, Y., Gan, C., & Su, B. (2022). Identification of
estrogen receptor down-regulators for endocrine resistant breast cancer. The Journal of Steroid Biochemistry
and Molecular Biology, 224, 106162. https://doi.org/10.1016/j.jsbmb.2022.106162
41. Nathan, M. R., & Schmid, P. (2017). A Review of Fulvestrant in Breast Cancer.
Oncology and Therapy, 5(1), 17–29. https://doi.org/10.1007/s40487-017-0046-2
42. Mottamal, M., Kang, B., Peng, X., & Wang, G. (2021). From Pure Antagonists to Pure Degraders of the
Estrogen Receptor: Evolving Strategies for the Same Target. ACS Omega, 6(14), 9334–9343.
https://doi.org/10.1021/acsomega.0c06362